2025 · 2nd Quarter (Apr 1 - June 30)

THE CAMPAIGN FOR SUSTAINABLE RX PRICING

Filed by MEHLMAN CONSULTING, INC..

Open official filing

Source-reported fields

Filing overview

Type: 2nd Quarter - Report
Posted: Jul 21, 2025
Income: $90,000.00
Expenses: Not reported
Registrant: MEHLMAN CONSULTING, INC.
Client: THE CAMPAIGN FOR SUSTAINABLE RX PRICING
Filing UUID: 2d749dba-2300-456e-bfdf-054c1b57d364
Termination date: Not reported

Literal source text

Lobbying issues and bill citations

MMM · Medicare/Medicaid

Prescription drug pricing issues. S. 229 Drug-price Transparency for Consumers (DTC) Act. H.R. 3789 - The Drug-price Transparency for Consumers (DTC) Act. H.R. 1 - One Big Beautiful Bill Act.

Literal federal measure citations: S. 229, H.R. 3789, H.R. 1

PHA · Pharmacy

Prescription drug pricing issues. H.R. 1843/S. 1302 - Increasing Transparency in Generic Drug Applications Act. S. 1954 - Biosimilar Red Tap Elimination Act.

Literal federal measure citations: H.R. 1843, S. 1302, S. 1954

CPT · Copyright/Patent/Trademark

Patent abuse issues. S.1040 - Drug Competition Enhancement Act. S.1041 - Affordable Prescriptions for Patients Act. S.1096 - Preserve Access to Affordable Generics and Biosimilars Act. S.1095 - Stop STALLING Act. S. 1097 - Interagency Patent Coordination and Improvement Act of 2025. S. 43 - Skinny Labels, Big Savings Act. H.R. 3269/S. 2276 - ETHIC Act.

Literal federal measure citations: S.1040, S.1041, S.1096, S.1095, S. 1097, S. 43, H.R. 3269, S. 2276

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.